Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam, Medtronic to Get Funding for Huntington's Disease Program

Premium

Alnylam Pharmaceuticals said this week that it has formed a collaboration with Medtronic and the CHDI Foundation to advance an siRNA-based treatment for Huntington's disease.

The drug, ALN-HTT, comprises an siRNA against huntingtin, the gene responsible for the disease, and a Medtronic-developed implantable infusion system designed to deliver the agent to the central nervous system.

CDHI, a non-profit firm focused on advancing Huntington's disease treatments, has agreed to initially fund up to 50 percent of the activities required to advance ALN-HTT up to an investigational new drug application filing.

Alnylam and Medtronic will maintain their existing 50/50 partnership on the drug, originally established in 2005 (GSN 2/11/2005).

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.